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The discovery of underlying molecular genetic abnormalities in gastrointestinal stromal tumors (GISTs) such as
activating mutations in the tyrosine kinase genes, KIT and platelet derived growth factor receptor-alpha (PDGFRA),
has led to remarkable clinical advances in treatment. Small molecule inhibitors such as imatinib and sunitinib are
known to inhibit the aberrantly activated KIT and PDGFRA receptor signaling and can lead to excellent clinical
outcomes for patients with GIST. Though the majority of GISTs appear to arise sporadically, a number of families
with high frequencies of GISTs have been reported and germline mutations have been identified. This review will
highlight the various inherited mutations associated with familial GIST syndromes and describe how an improved
understanding of these genetic syndromes has important clinical implications for future understanding of this
heterogeneous disease.
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Gastrointestinal stromal tumors (GISTs) are the most
common mesenchymal tumors arising in the gastro-
intestinal tract [1,2]. Though the majority of GISTs ap-
pear to arise sporadically, a number of families with high
frequencies of GISTs have been reported and germline
mutations have been identified [3]. The true frequency
of all GIST diagnoses has been difficult to determine be-
cause the definition of GIST was derived in 1990 before
it was molecularly characterized. One United States re-
port from the Surveillance, Epidemiology, and End
Results (SEER) database indicated that, from 1992 to
2000, the yearly incidence rate in the United States was
6.8 cases per million [4]. The reported US annual inci-
dence rate is slightly lower than incidence rates reported
in several international epidemiological studies with
highest described incidence of 14.5 cases per million in
Sweden [5-7]. Discrepancies between diagnostic criteria* Correspondence: robsonm@mskcc.org
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distribution, and reproduction in any mediumover the time period of data collection may have
accounted for some of the variation. No specific epi-
demiological risk factors for GIST have been described.
The majority of GISTs appear to be sporadic, but a
number of families with inherited predisposition to
GISTs have been identified. The first family with features
consistent with inherited GIST was reported in 1990,
but it was not until 1998 that Nishida and colleagues
identified the first germline mutation associated with fa-
milial predisposition to GIST [8,9]. In this Japanese fam-
ily, three individuals in two generations were diagnosed
with multiple GISTs. The germline DNA of the available
affected family members contained a mutation in exon
11 of c-KIT, which resulted in deletion of a valine resi-
due at codon 559_560 in the juxta-membrane domain of
the KIT protein. This same mutation was observed in
the subjects’ GIST tumors and resulted in constitutive
activation of KIT.
Since this first description of a family with an exon 11
KIT mutation, multiple other families with inherited
GIST syndromes have been described. Though many
have been found to have exon 11 KIT mutations, others
have alternative KIT mutations or mutations involvingCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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hydrogenase (SDH) genes [10-29]. Similarities exist
among the clinical features of these various germline fa-
milial GIST mutations, but each germline mutation can
manifest differently (Table 1).
C-kit mutations
Paralleling the high frequency of KIT mutations in spor-
adic GIST, most reported inherited GISTs have involved
families with germline mutations in the KIT gene, com-
monly in exon 11, which encodes the juxta-membrane
domain. In addition to the development of GISTs, these
families manifest variable clinical phenotypes that typic-
ally also include hyperpigmentation, urticaria pigment-
osa, and dysphagia. The specific KIT exon 11 deletion
mutation described in the first family with an identified
germline mutation in familial GIST, does not seem to be
required for the familial GIST syndrome as a similar
clinical phenotype involving hyperpigmentation and
GIST predisposition was seen in a Spanish family with
an alternative exon 11 KIT mutation consisting of a du-
plication of the sequence CAACTT [30].
Missense mutations involving exon 11 have been
implicated in similar familial GIST syndromes. Several
families have to found with germline point mutations
leading to the substitution of alanine for valine (559) inTable 1 Germline Mutations Associated with GIST Predisposit
Gene (Exon) Mutation Genera
C-KIT (11) V559del Hyperpi
CAACTTdup
V559A
W557R
C-KIT (17) D820Y Dyspha
C-KIT (13) K642E No hyp
PDGFRA* D846Y Large h
Y555C Lipoma
V561D
NF1** Many various mutations in
NF1 gene (>300 identified)
Café au
axillary/
SDHB, SDHC, and SDHD*** SDHB IVS1 + 1 G! T Paragan
SDHB c.423 + 1 G!C (Carney
SDHB c.45_46insCC
SDHC c.43 + 1 C! T
SDHC IVS5 + 1 G!A
SDHD c.57delG
*Platelet derived growth factor receptor-alpha.
**Neurofibromin 1.
***Succinate dehydrogenase (B, C, and D).the KIT juxta-membrane domain [31]. Another exon 11
KIT juxta-membrane missense mutation (W557R) was
described in a family consisting of 19 individuals of Ital-
ian ancestry who had variable expression of clinical
phenotype involving hyperpigmentation and dysphagia
[26]. Although the development of GIST was nearly uni-
form in this kindred, not all family members harboring
this specific germline mutation had hyperpigmentation
or dysphagia, suggesting a degree of variability of expres-
sion, even within a family with a specific KIT germline
mutation.
KIT exon 11 mutations are not the only KIT mutations
implicated in familial GIST syndromes. Hirota et al.
(2002) reported the first identified family with a germline
mutation in exon 17, encoding the KIT tyrosine kinase II
domain [32]. Though the precise clinical phenotype of
KIT mutations may be influenced by reporting, none of
the members of this family with KIT tyrosine kinase II
domain mutations had hyperpigmentation, differing from
some families with KIT exon 11 mutations. Dysphagia,
however, was a common similar complaint and suggests
dysphagia may be a feature more characteristic of germ-
line KIT mutations in general, rather than associated
with a specific mutation.
A third KIT mutation in exon 13 encoding the tyro-
sine kinase I domain, has also been implicated in familialion and Associated Clinical Features
l Clinical Features Reference
gmentation, urticaria pigmentosa, dysphagia Nishida 1998 [9]
Carballo 2005 [11]
Beghini 2001 [30]
Maeyama 2001 [31]
Robson 2004 [26]
gia but no hyperpigmentation Hirota 2002 [32]
erpigmentation and no urticaria pigmentosa Isozaki 2000 [33]
Graham 2007 [34]
ands Chompret 2004 [35]
s and small intestine fibrous tumors de Raedt 2006 [36]
Pasini 2007 [37]
lait spots, dermal neurofibromas,
inguinal freckling, ocular hamartomas
Relles 2010 [38]
glioma and pheochromocytoma Carney 2002 [39]
-Stratakis Syndrome) McWhinney 2007 [40]
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single base mutations in the tyrosine kinase I domain
resulting in a substitution of Glu for Lys (642) [33,34]. A
predisposition to GIST was present in these families but
not hyperpigmentation or urticaria pigmentosa, provid-
ing further support to the fact that specific KIT germline
mutations may lead to variable clinical phenotypes.
Mouse models with “knock-in” mutations, represent-
ing inherited GIST syndromes, additionally support the
slightly different clinical phenotypes associated with spe-
cific KIT mutations. Mice with the V558del mutation
(corresponding to the human exon 11 deletion muta-
tion) as well as the D818Y mutation (corresponding to
human exon 17 missense mutation) had interstitial cell
of Cajal hyperplasia and GISTs [41,42]. Only mice with
V558del had increased dermal mast cells, a finding not
seen in mice with the D818Y mutation. This suggests
the specific KIT exon 11 mutation may be required for
the feature of urticaria pigmentosa whereas development
of GIST may be a more generalized phenomenon, asso-
ciated with a broad spectrum of KIT activating germline
mutations. Despite the suggestion of genotype specific
clinical features, variability in patient reporting of add-
itional components of the inherited GIST syndrome may
complicate precise genotype-phenotype correlations as
suggested in one report [26].
PDGFRA mutations
Though the majority of described inherited GIST syn-
dromes have been associated with germline KIT muta-
tions, several families with inherited predisposition to
GISTs have been described with germline PDGFRA
mutations. One French family with five affected indivi-
duals was found to have a germline PDGFRA missense
mutation (2675 G>T), resulting in a tyrosine substitu-
tion for the highly conserved aspartic amino acid at
codon 846 which showed perfect cosegregation with the
GIST phenotype in the tested family members [35].
Affected individuals also had large hands whereas those
without the mutation, did not. Interestingly, the
PDGFRA Asp846Tyr mutation identified in this family is
homologous to codon 820, located on the KIT tyrosine
kinase II domain, the site of inherited GIST involving a
Japanese kindred of six affected family members [32].
Other PDGFRA mutations, in addition to Asp846Tyr,
have been associated with inherited GIST. Three sisters
who were affected with intestinal neurofibromatosis in
an autosomal dominant pattern of inheritance, without
other manifestations of neurofibromatosis 1 (NF1) or
neurofibromatosis 2 (NF2), underwent genetic screening,
and a PDGFRA Y555C mutation, located in the juxta-
membrane domain, was identified [36]. The similarity of
these tumors’ genetic composition and clinical phenotype
to GIST led the authors to conclude that intestinalneurofibromatosis is a specific subtype of KIT negative,
familial GIST, associated with PDGFRA mutations and
not a completely distinct disease. Affected individuals
had large hands, a finding similar to other families
described with inherited GIST and PDGFRA mutations,
though not described in familial GIST associated with
KIT germline mutations. None of the other related clin-
ical manifestations of inherited GIST (dysphagia, hyper-
pigmentation, urticaria pigmentosa) associated with
germline KIT mutations was seen in patients with
PDGFRA mutations.
A third PDGFRA germline missense mutation (V561D)
involving exon 12 was identified in a young female pa-
tient with several gastric GISTs [37]. This patient’s alter-
native germline PDGFRA mutation may have resulted in
her slightly different phenotype as she was noted to have,
in addition to gastric GISTs, multiple lipomas and fibrous
tumors of her small intestine. Lipomas and fibrous
tumors of the small intestine were not previously part of
other families described [35,36] with PDGFRA mutations
and predisposition to GIST nor where they a feature of
families with KIT germline mutations.
Neurofibromatosis type 1; von Recklinghausen’s
disease (NF1)
NF1 is a common genetic disorder occurring in approxi-
mately 1 in every 3,000 live births. The disease is classic-
ally associated with café au lait spots, multiple dermal
neurofibromas, axillary and inguinal freckling, and ocu-
lar hamartomas [43]. NF1 is inherited in an autosomal
dominant manner, and the mutated NF1 protein encodes
the GTPase activating protein neurofibromin.
Patients with NF1 have been felt to be at increased risk
of a variety of GI tumors. A previous report reviewing
the literature found that 34% of GI tract malignancies in
patients with NF1 were GISTs [38]. NF1 associated
GISTs are somewhat different than typical sporadic
GISTs as NF1 associated GISTs typically have neither
mutated KIT nor PDGFRA genes [44,45]. One series,
nevertheless, reported that a small number of NF1
patients did have KIT and PDGFRA mutations [46].
Since the majority of GISTs associated with NF1 muta-
tions do not have c-KIT or PDGFRA mutations, NF1
associated GISTs may have alternative pathogenesis
which may result in different clinical outcomes. The
majority of the tumors from patients in the series by
Miettinen et al. 2006 had small, mitotically inactive
tumors, and the majority of patients in this series with
long-term follow-up had good prognosis [44]. Whether
NF1 associated GISTs arise from a completely KIT inde-
pendent process or whether the mutated neurofibromin
protein indirectly activates KIT pathways carries signifi-
cant clinical implications. Therapies that directly target
KIT such as imatinib may not be effective in patients
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mutations in most cases of NF1 GIST, one case report
indicated disease stabilization with sunitinib [47].
Succinate dehydrogenase mutations
Succinate dehydrogenase (SDH) is an enzyme localized
to the inner mitochondrial membrane and is integral to
cellular respiration by participating in both the citric
acid cycle and the electron transport chain. SDH is com-
posed of four subunits (A-D), and mutations in the SDH
genes encoding each subunit have been associated with
various human diseases [48]. Not surprisingly, a number
of these diseases involve disordered mitochondrial res-
piration, resulting in severe metabolic and neurologic
dysfunction.
In addition to SDH’s critical role in cellular respiration,
SDH is believed to function as a tumor suppressor.
Mutations in SDH subunits B (SDHB), C (SDHC), and
D (SDHD), in particular, have been associated with fa-
milial cancer predisposition syndromes with affected
individuals at increased risk for the development of
paragangliomas and pheochromocytomas [10]. In 2002,
12 individuals from five unrelated families were found to
have developed paragangliomas and GISTs, and the
Carney-Stratakis Syndrome (CSS) was described [39].
CSS appears to be an autosomal dominant syndrome
with incomplete penetrance characterized by the devel-
opment of paraganglioma, GIST, or both. CSS has a vari-
able phenotypic expression as demonstrated by a report
of monozygotic twins with CSS where one developed a
paraganglioma and the other GIST [49]. To better
characterize the germline mutations present in patients
with CSS, genetic sequencing was performed for six
individuals in six unrelated families, and mutations in
SDHB, SDHC, and SDHD, were identified [40]. Differing
from most sporadic GISTs, no mutations in KIT or
PDGFRA were seen.
Additional recent work has confirmed the important
role SDH plays in the pathogenesis of GISTs. A study of
34 GIST patients without KIT or PDGFRA mutations
(WT GIST) revealed that four patients (12%) had SDH
germline mutations, even in the absence of a family or
personal history of paragangliomas. Further, even in
patients without germline SDH mutations, patients with
WT GISTs had complete loss or markedly reduced
SDHB protein expression compared to patients with
KIT mutant GIST. This further suggests the important
role of SDH in the pathogenesis of GIST, in addition to
cases where a germline mutation in SDH is found [50].
The finding of absent or low levels of SDH protein in
patients with CSS was confirmed by a study showing
that none of the four patients with CSS had positive
immunohistochemical staining for SDHB, even though
only one was found to have a germline mutation. Thiscontrasted starkly with KIT and PDGFRA mutant GIST
samples which all stained strongly for SDHB [12].
Though mutations in SDHB, SDHC, and SDHD, have
been described most thoroughly, recently two young
patients with GIST were found to have detectable muta-
tions in SDHA, representing the first described cases of
SDHA inactivation in GIST [51].
Deletions in chromosome 1 involving succinate
dehydrogenase C
Due to associations between SDH mutations and
patients with paraganglioma and GIST syndromes, the
presence of SDH mutations was evaluated in patients
with Carney Triad (CT), a similar, though distinct, syn-
drome from CSS [52]. CT is felt to be non-hereditary
and consists of having at least two of the triad of para-
ganglioma, GIST, and pulmonary chordoma. CT was
first described in 1977 when Carney and colleagues
reported seven unrelated women with the triad [14]. In
2007, comparative genomic hybridization studies were
performed on 41 tumor samples from 37 patients with
CT, and though no tumors had coding sequence muta-
tions of the investigated SDH genes, a number of DNA
copy changes were seen [52]. Particularly, deletions of
chromosome 1p and 1q12-q21, the site of the SDHC
gene, were found. Interestingly, other classic mutations
associated with GIST such as KIT and PDGFRA were
not found in these tumor specimens from patients with
CT. This finding is consistent with results from other
studies [15,53], raising the possibility that GISTs in CT
arise from alternative pathologic mechanisms from most
sporadic GISTs.
Consistent with an alternative genetic and possible
pathologic mechanism of tumorigenesis, GISTs in CT
behave differently clinically from most sporadic GISTs as
they affect young women and have been associated with
frequent lymph node metastasis, multifocality, and un-
predictable behavior [20]. In a review published in 1999,
Carney described a higher rate of gastric GIST and
metastatic disease at presentation [29]. How deletions of
chromosome 1p and 1q (in the region of the SDHC
gene) contribute to the alternative clinical behavior of
GISTs associated with CT remains to be explained.
Treatment of patients with inherited GIST
Although various germline mutations have been asso-
ciated with heterogeneous clinical syndromes, no data
currently exist that inherited GIST should be treated dif-
ferently from its sporadic counterpart. Nevertheless, on a
theoretical basis, increasing knowledge of the various
germline mutations associated with hereditary GIST sug-
gests that different clinical approaches may ultimately
show increased benefit. For example, when GIST is
present in patients with paragangliomas (Carney-Stratakis
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PDGFRA (WT GIST), these tumors theoretically may be
less sensitive to imatinib. This may also be true for inher-
ited GIST associated with NF1 mutations as KIT muta-
tions are only found in small proportions of NF1 GIST.
Clinical data are not yet available to address these theoret-
ical speculations.
Inherited GIST associated with CSS has been shown to
be related to deficits in SDH, and improved understand-
ing of the mechanisms surrounding SDH regulation may
lead to future therapeutic approaches. Unfortunately,
patients with advanced WT GIST when treated with
imatinib had decreased objective response, time to
tumor progression, and overall survival compared to
patients with KIT exon 11 mutations [54]. Mutations in
SDH and NF1 may explain the non-KIT mediated
pathogenesis in patients with WT GIST, and patients
with inherited SDH mutations, and possibly NF1 muta-
tions, may ultimately benefit from alternative targeted
treatment. The relationship between SDH and NF1 to
GIST pathogenesis will first need to be further clarified.
Patients whose GISTs are characterized by a deficiency
in SDHB by immunohistochemistry have been described
to have a somewhat different clinical course from the
majority of GIST patients. Specifically, one study found
that deficiency of SDHB was associated with a female
predominance, gastric primary location, lymph node in-
volvement, and similar morphology to GIST arising in
pediatric patients [55]. Since these patients’ GISTs fol-
lowed a more indolent course, SDHB deficient tumors
may ultimately need to be managed differently.
Sunitinib may be particularly helpful for patients with
GIST who develop resistance or intolerance to imatinib.
A study involving 97 patients with metastatic, imatinib-
resistant/intolerant GIST, demonstrated the particular
efficacy of sunitinib in patients with primary exon 9 and
WT GIST [56,57].
Conclusions
Gastrointestinal stromal tumors are the most common
mesenchymal tumor arising in the GI tract, and therapy
targeting the molecular abnormalities involved in GIST
pathogenesis has been a remarkable success in solid
tumor oncology. Improved recognition of the associated
clinical features of patients with inherited GIST likely to
harbor germline mutations will lead to appropriate gen-
etics evaluation and may influence family members
wishing to evaluate their risk. Unlike other cancer pre-
disposition syndromes such as Lynch Syndrome, some
of the germline mutations that result in inherited GIST,
such as mutations involving KIT and PDGFR genes, pro-
duce abnormal proteins that can be inhibited by cur-
rently available targeted therapy. Increasing knowledge
of novel inherited germline mutations predisposing toGIST, particularly wild-type inherited GIST, may lead to
improved understanding of perturbed molecular path-
ways in sporadic GIST as well. For instance, the recogni-
tion of genetic abnormalities in SDH in GISTs that are
not associated with KIT and PDGFRA mutations intro-
duces a new avenue of research that may have relevance
for sporadic disease.
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